Fate Therapeutics Cmn (FATE) 2.38 $FATE Fate

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Fate Therapeutics Cmn (FATE) 2.38 $FATE

Fate Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming investor conferences in September:
FATE: 2.38 (-0.07), WFC: 50.55 (+0.12)

Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 16, 2016 at 8:00 am ET.
FATE: 2.38 (-0.07)

Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 23% in the last trading session.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)

Fate Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection
FATE: 2.38 (-0.07)

Fate Therapeutics Announces $10.3 Million Common Stock Private Placement
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a private placement with a select group of institutional investors, including funds managed by Franklin Advisers, Inc., under which the investors have agreed to purchase 5,250,000 shares of the Company's common stock at a price of $1.96 per share, for gross proceeds of approximately $10.3 million. The Company expects to use the proceeds from the transaction primarily to advance its pipeline of programmed cellular immunotherapies and for general corporate purposes.
FATE: 2.38 (-0.07)

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, August 8, 2016 at 5:00 p.m. ET to report its second quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)

Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 2.38 (-0.07), ARNA: 1.57 (+0.01), EXEL: 11.54 (+0.19)

Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 2.38 (-0.07), JNJ: 119.32 (+0.24), GERN: 2.75 (+0.02), EXEL: 11.54 (+0.19)

Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) was a big mover last session, as its shares rose almost 6% on the day.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)

Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 2.38 (-0.07), NEO: 8.00 (+0.05)

Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 2.38 (-0.07)

Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 2.38 (-0.07)

Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 2.38 (-0.07)

Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 2.38 (-0.07)

Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 2.38 (-0.07)

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)

Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 2.38 (-0.07), ANIK: 47.89 (-0.05)

Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 2.38 (-0.07)

Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 2.38 (-0.07), VRTX: 95.11 (+0.36), LGND: 106.19 (-0.85), CELG: 105.49 (-0.88)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading